AtaiBeckley patents R-MDMA formulation and California warns about synthetic shrooms edibles

R-MDMA takes a step forward as AtaiBeckley receives a U.S. Patent and Trademark Office patent for EMP-01, an oral R-MDMA formulation. The newsletter links R-MDMA’s distinct pharmacology to earlier research suggesting it may activate serotonin receptors differently than racemic MDMA, and it notes plans for phase 2a study activity targeting social anxiety disorder in early 2026. California safety action targets “magic mushroom” edibles from TRE House. The California Department of Public Health warns consumers to avoid products claiming psilocybin-containing mushrooms, saying gummies, chocolate bars, and syrup contain 4-acetoxy-DET and some contain 4-acetoxy-DMT, both described as psilocin analogs, and notes potential risks including severe health effects. The issue also reports on naturalistic psychedelic-use outcomes related to adverse childhood experiences, finding many users report no difficulties but a subset reports longer-lasting difficult trips that correlate with higher ACE exposure.